Supplementary Tables S1 and S2 from Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy

Supplementary Table S1: List of patient tumor specimens used for RNA-seq and MSK-IMPACT analysis. *We note that two primary tumors in patients who responded to TAZ harbored deletions of RB1 (patient 2, sample ES_02_T_02) in one tumor and CDKN2A/B in another tumor (patient 5, sample ES_05_T_01). However, these primary tumors were fully resected prior to the initiation of TAZ treatment and did not recur at the primary sites. In the case of patient 2, a later TAZ-responsive metastasis (ES_2_T_03) did not harbor the RB1 loss. In the case of patient 5, a later TAZ-responsive metastasis (ES_05_T_09) did not harbor the CDKN2A/B loss. This suggests that these mutations were subclonal and were not present in tumors exposed to TAZ treatment. Thus, the mutations in these tumors were unlikely to have impacted their response to TAZ.
Supplementary Table S2: List of mutations found in all patient tumor specimens in Supplementary table 1 for which MSK-IMPACT data is available.